Nxera Pharma sues OMass Therapeutics for patent infringement over miniG technology.

Nxera Pharma's UK subsidiary has filed a patent infringement lawsuit against OMass Therapeutics, alleging violation of patents related to its miniG technology, a key part of its drug discovery platform. The case is underway in the UK Patents Court, with Nxera seeking compensation and an injunction to stop further infringement. This legal action highlights Nxera's efforts to protect its proprietary technology in the competitive biopharma sector. The company has not commented further as the matter is before the court.